Does the media refer more to NRIX or SGMT?

In the previous week, Sagimet Biosciences had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 4 mentions for Sagimet Biosciences and 3 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.96 beat Sagimet Biosciences' score of 0.47 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SGMT or NAMS?

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Sagimet Biosciences. MarketBeat recorded 9 mentions for NewAmsterdam Pharma and 4 mentions for Sagimet Biosciences. NewAmsterdam Pharma's average media sentiment score of 0.70 beat Sagimet Biosciences' score of 0.47 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is PHVS or SGMT more profitable?

Sagimet Biosciences' return on equity of -31.96% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Sagimet Biosciences N/A -31.96% -30.57%

Does the media refer more to PHVS or SGMT?

In the previous week, Pharvaris had 29 more articles in the media than Sagimet Biosciences. MarketBeat recorded 33 mentions for Pharvaris and 4 mentions for Sagimet Biosciences. Pharvaris' average media sentiment score of 0.50 beat Sagimet Biosciences' score of 0.47 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 12 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SGMT or PGEN?

In the previous week, Precigen had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Precigen and 4 mentions for Sagimet Biosciences. Precigen's average media sentiment score of 1.08 beat Sagimet Biosciences' score of 0.47 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRDN or SGMT?

In the previous week, Sagimet Biosciences had 1 more articles in the media than Viridian Therapeutics. MarketBeat recorded 4 mentions for Sagimet Biosciences and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.21 beat Sagimet Biosciences' score of 0.47 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sagimet Biosciences (SGMT) Competitors

$10.97 +0.51 (+4.89%)

As of 12:09 PM Eastern

Compare

SGMT vs. NRIX, NAMS, PHVS, PGEN, and VRDN

Should you buy Sagimet Biosciences stock or one of its competitors? Sagimet Biosciences's main competitors and comparable companies include Nurix Therapeutics (NRIX), NewAmsterdam Pharma (NAMS), Pharvaris (PHVS), Precigen (PGEN), and Viridian Therapeutics (VRDN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sagimet Biosciences compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Sagimet Biosciences (NASDAQ:SGMT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Nurix Therapeutics currently has a consensus target price of $34.21, suggesting a potential upside of 31.65%. Sagimet Biosciences has a consensus target price of $27.96, suggesting a potential upside of 155.45%. Given Sagimet Biosciences' higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sagimet Biosciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Sagimet Biosciences has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Sagimet Biosciences' return on equity of -31.96% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Nurix Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.45, indicating that its share price is 245% more volatile than the broader market.

87.9% of Sagimet Biosciences shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sagimet Biosciences has lower revenue, but higher earnings than Nurix Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	32.12	-$264.46M	-$3.45	N/A
Sagimet Biosciences	$2M	340.17	-$51.04M	-$1.28	N/A

In the previous week, Sagimet Biosciences had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 4 mentions for Sagimet Biosciences and 3 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.96 beat Sagimet Biosciences' score of 0.47 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sagimet Biosciences beats Nurix Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to NewAmsterdam Pharma?

Sagimet Biosciences (NASDAQ:SGMT) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Sagimet Biosciences presently has a consensus target price of $27.96, suggesting a potential upside of 155.45%. NewAmsterdam Pharma has a consensus target price of $49.73, suggesting a potential upside of 125.60%. Given Sagimet Biosciences' higher possible upside, analysts clearly believe Sagimet Biosciences is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Sagimet Biosciences has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	340.17	-$51.04M	-$1.28	N/A
NewAmsterdam Pharma	$22.50M	117.11	-$203.82M	-$2.16	N/A

Sagimet Biosciences has a beta of 3.45, suggesting that its share price is 245% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

Sagimet Biosciences has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Sagimet Biosciences' return on equity of -31.96% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Sagimet Biosciences. MarketBeat recorded 9 mentions for NewAmsterdam Pharma and 4 mentions for Sagimet Biosciences. NewAmsterdam Pharma's average media sentiment score of 0.70 beat Sagimet Biosciences' score of 0.47 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Sagimet Biosciences beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

How does Sagimet Biosciences compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Sagimet Biosciences (NASDAQ:SGMT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

In the previous week, Pharvaris had 29 more articles in the media than Sagimet Biosciences. MarketBeat recorded 33 mentions for Pharvaris and 4 mentions for Sagimet Biosciences. Pharvaris' average media sentiment score of 0.50 beat Sagimet Biosciences' score of 0.47 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	12 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sagimet Biosciences' return on equity of -31.96% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Sagimet Biosciences has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Sagimet Biosciences	$2M	340.17	-$51.04M	-$1.28	N/A

Pharvaris presently has a consensus target price of $59.87, suggesting a potential upside of 56.25%. Sagimet Biosciences has a consensus target price of $27.96, suggesting a potential upside of 155.45%. Given Sagimet Biosciences' higher possible upside, analysts clearly believe Sagimet Biosciences is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sagimet Biosciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Pharvaris has a beta of -2.33, meaning that its stock price is 333% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.45, meaning that its stock price is 245% more volatile than the broader market.

87.9% of Sagimet Biosciences shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sagimet Biosciences beats Pharvaris on 9 of the 14 factors compared between the two stocks.

How does Sagimet Biosciences compare to Precigen?

Sagimet Biosciences (NASDAQ:SGMT) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

In the previous week, Precigen had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Precigen and 4 mentions for Sagimet Biosciences. Precigen's average media sentiment score of 1.08 beat Sagimet Biosciences' score of 0.47 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sagimet Biosciences currently has a consensus target price of $27.96, indicating a potential upside of 155.45%. Precigen has a consensus target price of $14.50, indicating a potential upside of 85.30%. Given Sagimet Biosciences' higher probable upside, equities research analysts plainly believe Sagimet Biosciences is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Sagimet Biosciences has a beta of 3.45, suggesting that its share price is 245% more volatile than the broader market. Comparatively, Precigen has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

Sagimet Biosciences has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Precigen	-183.98%	423.75%	84.39%

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 41.4% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sagimet Biosciences has higher earnings, but lower revenue than Precigen. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	340.17	-$51.04M	-$1.28	N/A
Precigen	$9.68M	288.19	-$250.64M	-$1.04	N/A

Summary

Precigen beats Sagimet Biosciences on 10 of the 17 factors compared between the two stocks.

How does Sagimet Biosciences compare to Viridian Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Sagimet Biosciences (NASDAQ:SGMT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

87.9% of Sagimet Biosciences shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by company insiders. Comparatively, 11.5% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sagimet Biosciences has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Sagimet Biosciences' return on equity of -31.96% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Viridian Therapeutics currently has a consensus target price of $38.54, indicating a potential upside of 74.73%. Sagimet Biosciences has a consensus target price of $27.96, indicating a potential upside of 155.45%. Given Sagimet Biosciences' higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Sagimet Biosciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Sagimet Biosciences had 1 more articles in the media than Viridian Therapeutics. MarketBeat recorded 4 mentions for Sagimet Biosciences and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.21 beat Sagimet Biosciences' score of 0.47 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viridian Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.45, indicating that its share price is 245% more volatile than the broader market.

Sagimet Biosciences has lower revenue, but higher earnings than Viridian Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	35.27	-$342.60M	-$3.37	N/A
Sagimet Biosciences	$2M	340.17	-$51.04M	-$1.28	N/A

Summary

Sagimet Biosciences beats Viridian Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMT vs. The Competition

Export

Metric	Sagimet Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$681.96M	$3.90B	$7.24B	$15.21B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	-8.57	14.18	273.92	25.64
Price / Sales	340.17	1,393.59	639.38	89.95
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	3.20	15.35	10.47	6.31
Net Income	-$51.04M	-$22.78M	$3.49B	$357.96M
7 Day Performance	-1.04%	-0.65%	0.62%	0.48%
1 Month Performance	4.94%	-0.89%	0.02%	-3.02%
1 Year Performance	77.97%	41.47%	23.11%	7.17%

Sagimet Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMT Sagimet Biosciences	3.705 of 5 stars	$10.97 +4.9%	$27.96 +154.8%	+68.7%	$682.77M	$2M	N/A	16	Gap Up
NRIX Nurix Therapeutics	3.0185 of 5 stars	$24.70 -3.2%	$34.21 +38.5%	+198.0%	$2.56B	$36.77M	N/A	357	Gap Up
NAMS NewAmsterdam Pharma	3.1701 of 5 stars	$21.20 -5.2%	$49.73 +134.5%	-13.6%	$2.53B	$7.12M	N/A	100	News Coverage Insider Trade
PHVS Pharvaris	3.7219 of 5 stars	$38.11 -1.9%	$59.87 +57.1%	+57.7%	$2.49B	N/A	N/A	148	Analyst Forecast Insider Trade High Trading Volume
PGEN Precigen	4.2343 of 5 stars	$6.96 +1.5%	$14.50 +108.5%	+91.0%	$2.48B	$85.72M	N/A	47	Positive News Options Volume Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMT) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sagimet Biosciences (SGMT) Competitors

SGMT vs. NRIX, NAMS, PHVS, PGEN, and VRDN

How does Sagimet Biosciences compare to Nurix Therapeutics?

Summary

How does Sagimet Biosciences compare to NewAmsterdam Pharma?

Summary

How does Sagimet Biosciences compare to Pharvaris?

Summary

How does Sagimet Biosciences compare to Precigen?

Summary

How does Sagimet Biosciences compare to Viridian Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sagimet Biosciences (SGMT) Competitors

SGMT vs. NRIX, NAMS, PHVS, PGEN, and VRDN

How does Sagimet Biosciences compare to Nurix Therapeutics?

Do analysts prefer NRIX or SGMT?

Is NRIX or SGMT more profitable?

Which has more risk & volatility, NRIX or SGMT?

Do institutionals & insiders hold more shares of NRIX or SGMT?

Which has higher earnings and valuation, NRIX or SGMT?

Does the media refer more to NRIX or SGMT?

Summary

How does Sagimet Biosciences compare to NewAmsterdam Pharma?

Do analysts prefer SGMT or NAMS?

Which has higher valuation and earnings, SGMT or NAMS?

Which has more volatility & risk, SGMT or NAMS?

Is SGMT or NAMS more profitable?

Does the media prefer SGMT or NAMS?

Do institutionals and insiders hold more shares of SGMT or NAMS?

Summary

How does Sagimet Biosciences compare to Pharvaris?

Does the media refer more to PHVS or SGMT?

Is PHVS or SGMT more profitable?

Which has better earnings and valuation, PHVS or SGMT?

Do analysts rate PHVS or SGMT?

Which has more risk and volatility, PHVS or SGMT?

Do insiders and institutionals hold more shares of PHVS or SGMT?

Summary

How does Sagimet Biosciences compare to Precigen?

Does the media prefer SGMT or PGEN?

Do analysts rate SGMT or PGEN?

Which has more risk and volatility, SGMT or PGEN?

Is SGMT or PGEN more profitable?

Do insiders and institutionals have more ownership in SGMT or PGEN?

Which has stronger earnings and valuation, SGMT or PGEN?

Summary

How does Sagimet Biosciences compare to Viridian Therapeutics?

Do institutionals & insiders hold more shares of VRDN or SGMT?

Is VRDN or SGMT more profitable?

Do analysts rate VRDN or SGMT?

Does the media favor VRDN or SGMT?

Which has more volatility and risk, VRDN or SGMT?

Which has preferable earnings and valuation, VRDN or SGMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools